No announcement yet.

Nervgen pharma

  • Filter
  • Time
  • Show
Clear All
new posts

  • Nervgen pharma

    NervGen Pharma to Collaborate on Chronic Spinal Cord Injury Study Sponsored by the State of Ohio / Ohio Department of Higher Education Awards $250,000 Grant To Dr. Jerry Silver, Co-inventor of NervGen’s Lead Compound

    Vancouver, Canada. June 22, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Dr. Jerry Silver of Case Western Reserve University (“CWRU”) in Cleveland, Ohio, has been awarded a research grant by the State of Ohio to conduct preclinical studies in spinal cord injury in collaboration with NervGen, including the effect of NVG-291 in a chronic setting. Dr. Silver is a renowned spinal cord injury and regenerative medicine researcher and Professor of Neurosciences at CWRU, as well as the co-inventor of NervGen’s lead compound, NVG-291.

    The State of Ohio, through the Ohio Department of Higher Education, has awarded Dr. Silver and CWRU the Third Frontier Research Initiative grant for principal investigators conducting research in spinal cord injury. The $250,000 grant will support the study entitled “Overcoming Inhibitory Proteoglycans to Promote Recovery after Chronic Spinal Cord Injury” for the fiscal years 2020 and 2021. The preclinical study will investigate PTPσ inhibition and/or a perineuronal net synthesis inhibitor for the treatment of acute (treatment begins one day post-injury) and chronic (treatment begins 12 weeks post-injury) cervical spinal cord injuries and will also investigate how physical rehabilitation aids the recovery process. NervGen will contribute the equivalent of $110,000 by providing manufactured drug product, as well as technical and drug development expertise to the design and review of the study by NervGen employees.

    “NervGen is very proud to be supporting Dr. Silver and his team, particularly this important work aimed at finding a treatment for those that are chronically affected by spinal cord injury,” stated Paul Brennan, NervGen’s President & CEO. “To date, there has been very little evidence or hope that a pharmaceutical therapy might have a meaningful effect in patients with a chronic condition. However, the work that Dr. Silver has conducted on understanding the role of chondroitin sulfate proteoglycans (“CSPGs”) in inhibiting nerve repair in both an acute and chronic setting has been critical in understanding the route to a potential therapeutic.”

    Dr. Silver commented, “Thus far, NVG-291 has produced unprecedented results in preclinical studies of acute spinal cord injury. The effect seen in these models is a result of NVG-291 acting to inhibit the negative effects of CSPGs on nerve repair. There is also compelling evidence to suggest that CSPGs play a critical role in inhibiting nerve repair in a chronic setting. In this context, we expect that NVG-291 should also demonstrate an effect in chronic models of spinal cord injury. The studies that have been sponsored by the Ohio Department of Higher Education will be an important step in testing this hypothesis.”

    Mr. Brennan also added, “We are particularly excited about the data that will be generated in this study in the chronic setting. In addition to the work that Dr. Silver is conducting in this study, NervGen and our collaborators are undertaking, and plan to undertake, a number of additional preclinical studies in chronic spinal cord injury as we move NVG-291 towards the clinic. We understand the significant unmet medical need that exists in this patient population, and it is our goal that NVG-291 will offer these patients a meaningful treatment option in the future.”

    "I'm manic as hell-
    But I'm goin' strong-
    Left my meds on the sink again-
    My head will be racing by lunchtime"

    <----Scott Weiland---->

  • #2
    I'm confused I thought they where already working on Chronic SCI? I thought the clinical trial that was going to start was going to be for chronic injuries?